Biopharma Business

Tag "disease"

Debiopharm’s triptorelin 6-month formulation receives EU approval

Debiopharm International, a Swiss-based company, part of Debiopharm Group, announced that triptorelin 6-month formulation (Decapeptyl and Pamorelin 22.5 mg) received approval for the treatment of central precocious puberty (CPP) in

Read Full Article

Upcoming Events


The Magazine

New Subscriber

Subscribe Here